The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2020 | ClarIDHy: ivosidenib in CCA
Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, outlines novel targeted therapies in cholangiocarcinoma (CCA). Specifically discussed is results from the Phase III ClarIDHy study (NCT02989857), evaluating ivosidenib in IDH1-mutant, chemotherapy-refractory CCA. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
